Wholesale CAS 25316-40-9 Doxorubicin Hydrochloride Doxorubicin

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Doxorubicin
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Orange to Red Powder
• Purity: >99%
• Product Name: Doxorubicin
• Name: Doxorubicin Powder
• Grade: Pharmaceutical Grade
• Assay: 99%
• Test Method: HPLC
• Application: Anti Cancer
• Specific: COA
• Mf: C27h29no11
• MW: 543.52
• Einecs No.: 255-446-0
• Melting Point: 205ºC
• Boiling Point: 617.77°c
• pH: 9
• Fash Point: 443.8 ºC
• CAS: 23214-92-8
• Transport Package: Negotiable
• Specification: Negotiable
• Trademark: QS-Doxorubicin
• Origin: Shaanxi Xi′ an
• Production Capacity: 2000kg/Month

Product Description

Wholesale CAS 25316-40-9 Doxorubicin Hydrochloride Doxorubicin

Product Description

Product Details

Product Name	Doxorubicin
CAS No.	23214-92-8
Appearance	Orange to red powder
MF	C6H12N2O4Pt
MW	543.52

Doxorubicin is an anti-tumor antibiotic that can inhibit the synthesis of RNA and DNA. It has the strongest inhibitory effect on RNA, a wide anti-tumor spectrum, and has effects on various tumors. It belongs to the non-specific drug of the cycle and has a killing effect on tumor cells of various growth cycles. It is mainly suitable for acute leukemia and is effective for both acute lymphocytic leukemia and myeloid leukemia. It is generally used as a second-line drug and can be considered for use when the first choice drug is resistant. Malignant lymphoma can be used as the preferred drug for alternate use. Breast cancer, sarcoma, lung cancer, bladder cancer and other cancers have certain curative effects. They are often used in combination with other anti-cancer drugs. The main toxic reactions are leukopenia and thrombocytopenia, which can occur in approximately 60% to 80% of patients; 100% of patients have varying degrees of hair loss, which can be restored to growth after discontinuation of medication; Cardiac toxicity, manifested as arrhythmia and ST-T changes, often occurs 1-6 months after discontinuation of medication. Early use of vitamin B6 and coenzyme Q10 can reduce their toxicity to the heart; Nausea and decreased appetite; Drug overflow outside the blood vessels can cause tissue ulcers and necrosis. In addition, urine may appear red after medication.

Application&Function

Various bone marrow inhibitors, especially nitrosamines, high-dose cyclophosphamide or methotrexate, mitomycin, or radiotherapy, when used in combination with doxorubicin, should be reduced in both the single dose and total dose of doxorubicin.
2. When used together with Lianzuo Xing, the latter can prolong the half-life of the product, so the dose of amphotericin should be reduced accordingly.
3. Any drug that may cause liver damage, such as when used in combination with doxorubicin, can increase liver toxicity; Mixing with heparin, cephalosporins, etc. can easily lead to precipitation.
4. Cross resistance with erythromycin. It does not exhibit cross resistance with methotrexate, fluorouracil, cytarabine, nitrogen mustard, mitomycin C, bleomycin, cyclophosphamide, and nitrosamines, and has varying degrees of synergistic effects when used in combination with cyclophosphamide, fluorouracil, methotrexate, cisplatin, and nitrosamines.
5. Be cautious when administering live virus vaccines during medication.
6. Can reduce the anticoagulant effect of heparin. The combination of Pucamycin and Doxorubicin may lead to fatal cardiac toxicity; Combined , it can enhance the inhibition of mitochondrial respiratory enzyme activity and increase cardiac toxicity.

Specification